CONTENTS
· Invitation
· Faculty
· Scientific Agenda
· Continuing
  Medical Education
· Call for Abstracts
· Who Should Attend?
· Objectives
· Registration
· General Information
· Hotel
  Accommodations
· Organizer

Dear Colleagues,

On behalf of the Organizing Committee, it is with great pleasure that we invite you to participate in the Joint Meeting of the 4th ISC International Conference on Cancer Therapeutics and the 7th Princess Margaret Hospital Conference: New Developments in Cancer Management, to be held November 15-17, 2007 in Toronto, Ontario, Canada.  This year we are especially proud that the ISC has joined their conference with Princess Margaret Hospital’s so we may present an even more comprehensive educational opportunity.

Year after year, this conference enjoys great success, as indicated by participant evaluations.  Attendees have offered praise for the quality of the scientific agenda and the speakers, and state that participation in the conference greatly enhances their knowledge of state-of-the-art cancer research and management.
This year, the Committee has organized yet another excellent agenda aimed at updating attendees on standard cancer therapies and new experimental programs, with in-depth examination of currently available targeted agents and their future role in clinical practice. The general focus of the discussions is to highlight how new information may apply to the treatment of cancer patients in your own institution or practice setting. The distinguished faculty includes members of the Princess Margaret Hospital community, one of the largest multidisciplinary cancer centers in North America and a pioneer in basic research and development of new cancer treatments.  In addition, the program will feature internationally renowned experts in various fields of oncology.

We are particularly proud to hold this meeting in the city of Toronto, one of the most beautiful and safest cities in North America.  Excellent museums and interesting sites abound throughout the city, which is also located less than two hours from Niagara Falls, one of the natural wonders of the world. Because of the city’s multicultural character, there are plenty of restaurant choices to sample cuisine that is among the best in the world. We hope you will make time to partake in all the city has to offer while updating your knowledge in state-of-the-art cancer research and management. 

We look forward to welcoming you to Toronto in November 2007!

Sincerely,
Ronald Feld, MD

Robert Bell, MD
University Health Network, Toronto, Ontario, Canada

Andrea Bezjak, MD
Princess Margaret Hospital
Toronto, Ontario, Canada

Anthony Brade, MD, CM, PhD
Princess Margaret Hospital
Toronto, Ontario, Canada

Joseph Brandwein, MD
Princess Margaret Hospital
Toronto, Ontario, Canada

Robert G. Bristow, MD, PhD
Princess Margaret Hospital
Toronto, Ontario, Canada

Ronald L. Burkes, MD
Mount Sinai Hospital
Toronto, Ontario, Canada

Eric X. Chen, MD, PhD
Princess Margaret Hospital
Toronto, Ontario, Canada

Michael Crump, MD
Princess Margaret Hospital
Toronto, Ontario, Canada

Gail E. Darling, MD
Princess Margaret Hospital
Toronto, Ontario, Canada

Laura A. Dawson, MD
Princess Margaret Hospital
Toronto, Ontario, Canada

William K. Evans, MD
Juravinski Cancer Center at Hamilton Health Services
Hamilton, Ontario, Canada

Ronald Feld, MD
Princess Margaret Hospital
Toronto, Ontario, Canada

Neil Fleshner, MD, PhD
Princess Margaret Hospital
Toronto, Ontario, Canada

Marc Freeman, MD
Toronto General Hospital
Toronto, Ontario, Canada

Steven Gallinger, MD
Mount Sinai Hospital
Toronto, Ontario, Canada

Guiseppe Giaccone, MD, PhD
National Cancer Institute
Bethesda, Maryland,
United States

Mary K. Gospodarowicz, MD
Princess Margaret Hospital
Toronto, Ontario, Canada

Richard Gralla, MD
New York Lung Cancer Alliance
New York, New York
United States

David W. Hedley, MD
Princess Margaret Hospital
Toronto, Ontario, Canada

John R. Kachura, MD
Toronto General Hospital
Toronto, Ontario, Canada

Robert S. Kerbel, PhD
Sunnybrook and Women’s College Health Sciences Centre and the University of Toronto
Toronto, Ontario, Canada

Vishal Kukreti, MD
Princess Margaret Hospital
Toronto, Ontario, Canada

Natasha Leighl, MD
Princess Margaret Hospital
University of Toronto
Toronto, Canada, Ontario

Jeffrey H. Lipton, MD, PhD
Princess Margaret Hospital
Toronto, Ontario, Canada

Geoffrey Liu, MD
Princess Margaret Hospital
Toronto, Ontario, Canada

Tak W. Mak, PhD
Princess Margaret Hospital
Toronto, Ontario, Canada

Warren P. Mason, MD, PhD
Princess Margaret Hospital
Toronto, Ontario, Canada

Cynthia Ménard, MD
Princess Margaret Hospital
Toronto, Ontario, Canada

Hans A. Messner, MD, PhD
Princess Margaret Hosptial
Toronto, Ontario, Canada

Ur Metser, MD
Princess Margaret Hospital
Toronto, Ontario, Canada

Enrico Mini, MD, PhD
University of Florence
Florence, Italy

Joseph Mikhael, MD
Princess Margaret HospitalToronto, Ontario, Canada

Tony S. Mok, MD
The Chinese University of
Hong Kong
Hong Kong, China

Malcom J. Moore, MD
Princess Margaret Hospital
Toronto, Ontario, Canada

Robert J. Motzer, MD
Memorial Sloan-Kettering Cancer Center
New York, New York
United States

Steven Narod, MD
Women’s College Hospital
Centre for Research in Women’s Health,
Toronto, Ontario, Canada

Tracy Nagy, RN
Princess Margaret Hospital
Toronto, Ontario, Canada

Martin E. O’Malley, MB
Toronto General Hospital
Toronto, Ontario, Canada

Mary F. Quinn, RN, BSN, OCN
University of Maryland
Baltimore, Maryland
United States

Kathy I. Pritchard, MD,
Toronto Sunnybrook Regional Cancer Center
Toronto, Ontario, Canada

Nagahiro Saijo, MD, PhD
National Cancer Center
Hospital East
Chiba, Japan

Edward A. Sausville, MD, PhD
University of Maryland
Baltimore, Maryland,
United States

Frances A. Sheperd, MD
Princess Margaret Hospital
Toronto, Ontario, Canada

Christine Simmons, MD
Princess Margaret Hospital
Toronto, Ontario, Canada

Lillian L. Siu, MD, FRCPC
Princess Margaret Hospital
Toronto, Ontario, Canada

Srikala Sridhar, MD
Princess Margaret Hospital
Toronto, Ontario, Canada

John Trachtenberg, MD
Princess Margaret Hospital
Toronto, Ontario, Canada

Ming-Sound Tsao, MD
Princess Margaret Hospital
Toronto, Ontario, Canada

David Warr, MD
Princess Margaret Hospital
Toronto, Canada, Ontario

Janice Wright, RN
Princess Margaret Hospital
Toronto, Ontario, Canada

Karen W.L. Yee, MD
Princess Margaret Hospital
Toronto, Ontario, Canada

Alexandre Zlotta, MD
Mount Sinai Hosipital
Toronto, Ontario, Canada

Thursday, November 15, 2007

Keynote Lecture (Insert Lecture Logo)
Chair: Ronald Feld, MD

How a targeted antiangiogenic drug may amplify the efficacy of conventional chemotherapy
Robert S. Kerbel, PhD

Going beneath the surface: Novel agents for downstream signaling targets
David W. Hedley, MD

Targeted therapies for CNS malignancies
Warren P. Mason, MD, PhD

Epigenetic therapies: HDAC inhibition
Edward A. Sausville, MD, PhD

Session II: Lung cancer  (Insert Lecture Logo)
Chairs: Ronald L. Burkes, MD and Giuseppe Giaccone, MD, PhD

Targeted therapy in NSCLC
Frances A. Shepherd, MD

East meets West: Global perspectives on TKIs
Tony S. Mok, MD

The role of platinum in the treatment of elderly patients with NSCLC
Nagahiro Saijo, MD, PhD

Surgical debate: Is there a role for surgery in stage IIIA NSCLC?
Yes: Gail E. Darling, MD
No: Giuseppe Giaccone, MD, PhD

Session III: Gastrointestinal malignancies  (Insert Lecture Logo)
Chair: Eric X. Chen, MD, PhD

Targeted therapy in colorectal cancer
Enrico Mini, MD, PhD

Targeted therapy of pancreas
Malcolm J. Moore, MD

Resection of liver mets
Steven Gallinger, MD

Liver radiotherapy
Laura A. Dawson, MD

Friday, November 16, 2007

Welcome to day two
Ronald Feld, MD

Session IV: Medical Imaging and Intervention
Chair: Martin E. O’Malley, MD

Role of PET in the management of malignant disease
Marc Freeman, MD

PET/CT for GI tumors
Ur Metser, MD

Radiofrequency ablation of tumors: Current status
John R. Kachura, MD

Session V: Genitourinary
Chairs: Neil Fleshner, MD and Srikala Sridhar, MD

Image guided therapy in prostate cancer
John Trachtenberg, MD

New targeted therapies in renal cell carcinoma
Robert J. Motzer, MD

Targeted radiotherapy in urologic cancer
Cynthia Ménard, MD

Session VI: Targeted therapies II 
Chair: Mary K. Gospodarowicz, MD

Measuring residual DNA damage in situ as a clinical biomarker of molecular
target inhibition in radiotherapy and chemotherapy trials
Robert G. Bristow, MD, PhD

Challenges in the design of early phase clinical trials evaluating
combinations of radiotherapy and molecularly targeted therapies
Anthony Brade, MD, PhD

Lunch

Session VII: Malignant hematology
Chairs: Hans A. Messner, MD, PhD and Michael R. Crump, MD

Update on chelation therapy
Karen W.L. Yee, MD

Management of patients with CML: Beyond imatinib
Jeffrey H. Lipton, MD, PhD

Management of the elderly with acute myeloid leukemia
Joseph Brandwein, MD

Targeted therapy for lymphoma
Michael R. Crump, MD

Session VIII: Targeted therapies III 
Chair: Richard Gralla, MD

Future of targeted therapy in cancer
Tak W. Mak, PhD

Pharmacoeconomics of targeted therapies
William K. Evans, MD

Targeted therapy in the elderly
Lillian L. Siu, MD

Saturday, November 17, 2007

Welcome to day three
Ronald Feld, MD

Session IX: Targeted therapies IV 
Chair: Enrico Mini, MD, PhD

Pharmacogenomic markers in lung cancer
Geoffrey Liu, MD

Pharmacogenomic markers in colorectal cancer: Current achievements and future prospects
Enrico Mini, MD, PhD

Session X: Breast cancer
Chairs: Natasha Leighl, MD and David Warr, MD

Targeted therapy: Targeting tumors or targeting patients?
Christine Simmons, MD

Targeting brca1 associated breast cancer
Steven Narod, MD

Choosing adjuvant therapy in the molecular era
Kathy I. Pritchard, MD, PhD

Session XI: Supportive Care: Managing Toxicities of Targeted Agents 
Chairs: Janice Wright, RN, MS, ACNP, and Richard Gralla, MD

Toxicities of molecularly targeted therapies
Richard Gralla, MD

A clinical approach to the assessment of common toxicities of targeted therapy
Mary F. Quinn, RN, BSN, OCN

Safety and efficacy of rituximab abbreviated infusion
Tracy Nagy, RN

Session XII: Challenging cases
Chair: Joseph Mikhael, MD

Challenging cases:

Bladder cancer: Adjuvant versus neoadjuvant therapies
Srikala Sridhar, MD,
Alexandre Zlotta, MD

Lymphoma: Maintenance therapy
Vishal Kukreti, MD

Locally advanced lung cancer: Combined modality therapy
Andrea Bezjak, MD
Natasha Leighl, MD

Closing remarks
Ronald Feld, MD

Imedex, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Imedex, LLC designates this educational activity for a maximum 18.5 hours of AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Canadian Accreditation
This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of The Royal College of Physicians and Surgeons of Canada, approved by the University of Toronto.

The Continuing Education Office, Faculty of Medicine, University of Toronto designates this educational activity for a maximum of 18 category 1 credits toward The AMA Physician's Recognition Award.  Each physician should claim only those credits that he/she actually spent in the activity.

Participants interested in presenting data should submit abstracts online at www.imedex.com by August 28, 2007. Abstracts are subject to acceptance by the Scientific Committee. Once accepted, abstracts will be published in the final course book and scheduled for oral or poster presentation.

Acceptance notifications and guidelines for poster presentation will be sent on September 27, 2007. Authors of accepted abstracts who have not registered will have until November 1, 2007 to do so at the rate of $295. After this date, abstracts without registered presenters will be disregarded.

Abstract Guidelines

• Abstract Guidelines
• Go to www.imedex.com and click “Abstracts”
• Follow the online instructions
• Abstracts must be written in English
• Accepted format: Word document format, 9 point Arial font, 500 word count limit
• Use a concise title
• List affiliations of author(s) as briefly as possible, with city, state and country
• Place an asterisk (*) before the name of the presenting author
• Use standard and well-accepted abbreviations
• When using references, use standard and well-accepted formats
• Abstract content should be single-spaced, typed in lower case and contain:
  – Purpose of the study
  – Summarized description of the project
  – Results and conclusions
  

Submission Deadline: August 28, 2007